- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04460027
W-SUDs for COVID-19
Woebot for Substance Use Disorders During COVID-19
The purpose of this study is to test the efficacy of a substance use disorder intervention delivered via a mobile application in an adult population during the COVID-19 pandemic.
This study that will test the comparative efficacy of the mobile-app based substance use disorder program to reduce substance use relative to a wait list control condition, and explore between group differences on quality of life indices as well as retention and engagement during COVID-19.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Palo Alto, California, United States, 94306
- Stanford University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All genders aged 18-65 years
- Access to a smartphone
- Available and committed to engage with app and complete assessments
- Be willing to provide email address (as this is how assessment incentives will be distributed),
- Literate in English (as W-SUDs conversational and video materials will be in English).
Exclusion Criteria:
- Pregnancy (as W-SUDs will not be specifically developed to address the unique needs of this population)
- History of severe drug/alcohol use
- History of opioid misuse without medication-assisted treatment
- Suicide attempt within the past year
- Opioid overdose within the past year
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: W-SUDs
|
Woebot Substance Use Disorder is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation.
|
No Intervention: Wait List Control
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Number of Substance Use Occasions in the Past 30 Days From Baseline to Post-treatment at 8 Weeks
Time Frame: Change from Baseline to Post-treatment at 8 weeks
|
Change in number of substance use occasions in the past 30 days from Baseline to Post-treatment at 8 weeks
|
Change from Baseline to Post-treatment at 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Short Inventory of Problems - Alcohol and Drugs (SIP-AD) From Baseline to Post-treatment at 8 Weeks
Time Frame: Change from Baseline to Post-treatment at 8 weeks
|
Measure of substance use problems.
The SIP-AD assesses substance use problems in the past 30 days.
Total score consists of of the sum of all 15 items, ranging from 0-45, where greater scores indicate greater substance use problems.
|
Change from Baseline to Post-treatment at 8 weeks
|
Change in Drug Abuse Screening Test (DAST-10) From Baseline to Post-treatment at 8 Weeks
Time Frame: Change from Baseline to Post-treatment at 8 weeks
|
Measure of drug abuse related consequences.
The DAST-10 is a brief, 10-item self-report measure that assesses consequences related to drug abuse, excluding alcohol and tobacco.
The range is 0-10, where higher scores indicate greater severity.
Adapted from past 12 months to past 30 days.
|
Change from Baseline to Post-treatment at 8 weeks
|
Change in Brief Situational Confidence Questionnaire (BSCQ) From Baseline to Post-treatment at 8 Weeks
Time Frame: Change from Baseline to Post-treatment at 8 weeks
|
Measure of self-confidence.
The 8-item BSCQ is a state dependent measure that assesses self-confidence to resist the urge to drink heavily or use drugs in a variety of situations.
Each of the 8 scale situations consists of a 100-mm line, anchored by 0% ("not at all confident") and 100% ("totally confident") where clients are asked to indicate confidence on a scale from 0% to 100%.
Higher scores are associated with greater confidence.
|
Change from Baseline to Post-treatment at 8 weeks
|
Change in Craving Ratings From Baseline to Post-treatment at 8 Weeks
Time Frame: Change from Baseline to Post-treatment at 8 weeks
|
A one-item, self-reported rating of craving intensity to use substances over the past 7 days.
Score ranges is from 0-4, where a greater score indicates a more intense urge to use.
|
Change from Baseline to Post-treatment at 8 weeks
|
Change in Pain Ratings From Baseline to Post-treatment at 8 Weeks
Time Frame: Change from Baseline to Post-treatment at 8 Weeks
|
A one item, self-reported rating of pain.
Scores range from 0-100 where higher scores indicate greater levels of pain.
|
Change from Baseline to Post-treatment at 8 Weeks
|
Change in Patient Health Questionnaire-8 (PHQ-8) From Baseline to Post-treatment at 8 Weeks
Time Frame: Change from Baseline to Post-treatment at 8 weeks
|
Measure of depression.
An 8-item self-report questionnaire that assesses the frequency and severity of depression symptoms.
Total scores range from 0 to 24 where higher scores indicate greater levels of depression.
|
Change from Baseline to Post-treatment at 8 weeks
|
Change in General Anxiety Disorder (GAD-7) From Baseline to Post-treatment at 8 Weeks
Time Frame: Change from Baseline to Post-treatment at 8 weeks
|
Measure of anxiety.
A 7-item brief self-report measure used to assess the frequency and severity of anxious thoughts and behaviors over the past 2 weeks.
Total score between 0-21, where higher scores indicate greater levels of anxiety.
|
Change from Baseline to Post-treatment at 8 weeks
|
Change in CAIR Pandemic Impact Questionnaire (CAIR-PIQ) From Baseline to Post-treatment at 8 Weeks
Time Frame: Change from Baseline to Post-treatment at 8 weeks
|
Assesses impact of the COVID-19 pandemic in terms of exposure to stressors, mental health impact, and growth.
Possible total score range from 0-22, where greater scores are related to greater impact.
|
Change from Baseline to Post-treatment at 8 weeks
|
Client Satisfaction Questionnaire (CSQ) at Post-treatment at 8 Weeks
Time Frame: Post-treatment (8 weeks from Baseline)
|
Measure of satisfaction.
An 8-item measure used to assess client's satisfaction with treatment on a 4-point scale.
Example questions include, "How would you rate the quality of service you received"?
and "Did you get the kind of service you wanted?"
Total sums range from 8-32, with high scores indicating greater satisfaction with the W-SUDs mobile application.
|
Post-treatment (8 weeks from Baseline)
|
Usage Rating Profile - Intervention (URPI)-Acceptability at Post-treatment at 8 Weeks
Time Frame: Post-treatment (8 weeks from Baseline)
|
Measure of acceptability.
A 6-item subscale that inquires about intervention acceptability.
Total scores range from 6-36, where greater scores indicate greater intervention acceptability.
|
Post-treatment (8 weeks from Baseline)
|
Usage Rating Profile - Intervention (URPI)-Feasibility at Post-treatment at 8 Weeks
Time Frame: Post-treatment (8 weeks from Baseline)
|
Measure of feasibility.
A 6-item subscale that inquires about factors that impact treatment usage (i.e., intervention quality).
Total scores range from 6-36, where greater scores indicate greater intervention feasibility.
|
Post-treatment (8 weeks from Baseline)
|
Change in Working Alliance Inventory (WAI-SR) From Mid-treatment at 4 Weeks to Post-treatment at 8 Weeks
Time Frame: Change from Mid-treatment at 4 weeks to Post-treatment at 8 weeks
|
Measure of working alliance.
A measure of therapeutic alliance that assesses three key aspects of the therapeutic alliance: (a) agreement on the tasks of therapy, (b) agreement on the goals of therapy and (c) development of an affective bond.
Total scores range from 12-60, with higher scores indicating greater alliance.
The present study utilized the validated 12-item Short-Revised version (WAI-SR) with minor changes to language, replacing "therapist" with "Woebot".
|
Change from Mid-treatment at 4 weeks to Post-treatment at 8 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 56439
- 4R44DA048712-02 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Substance Use Disorders
-
Icahn School of Medicine at Mount SinaiNational Institute on Drug Abuse (NIDA)RecruitingSubstance Use Disorder | Cocaine Use DisorderUnited States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)RecruitingSubstance Use | Substance Use Disorders | Cannabis Use | Alcohol Use, UnspecifiedUnited States
-
Woebot HealthNational Institute on Drug Abuse (NIDA); Stanford UniversityCompletedSubstance Use Disorders | Alcohol Use Disorder (AUD)United States
-
University of MichiganNational Institute on Alcohol Abuse and Alcoholism (NIAAA)RecruitingSubstance Use | Substance Use Disorders | Substance DependenceUnited States
-
Emory UniversityNational Institute on Drug Abuse (NIDA); Georgia Institute of Technology; CUNYCompletedSubstance-Related Disorders | Substance Abuse, Intravenous | Substance Use Disorders | Opioid Use | Substance Abuse | Opioid-use Disorder | Opioid Use Disorder, Severe | Substance WithdrawalUnited States
-
Woebot HealthStanford UniversityCompletedSubstance Use Disorders | Alcohol Use Disorder (AUD)United States
-
Wake Forest University Health SciencesNational Institute on Drug Abuse (NIDA)RecruitingSubstance Use | Opioid Use | Drug Use | Substance MisuseUnited States
-
Centre for Addiction and Mental HealthUniversity of Missouri, St. LouisCompletedSubstance Use Disorders | Alcohol Use DisorderCanada
-
Istanbul UniversityCompletedSubstance Use | Substance Use Disorders | Substance AbuseTurkey
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)CompletedPTSD | Alcohol Use Disorders | Substance Use DisordersUnited States
Clinical Trials on Woebot Substance Use Disorder
-
University of California, Los AngelesNational Institute on Drug Abuse (NIDA)Completed
-
Sorlandet Hospital HFUniversity of OsloCompletedHealth, Subjective | Tobacco Use | Opioid Use Disorder | Substance Use Disorders | Mental Health ImpairmentNorway
-
West China HospitalCompletedPreoperative Screen for Substance Abuse in in Patients Undergoing Emergency OperationChina
-
University of OsloSINTEF Health ResearchCompletedIntegrated Treatment to Persons With Mental Disorders and Co-occurring Substance Use Disorders (ROP)Mood Disorders | Anxiety Disorders | Substance Use Disorders
-
Wayne State UniversityLoyola University ChicagoCompletedHIV Infections | Substance Use Disorders | Social Stigma | Physician-Patient RelationsUnited States
-
Rosalind Franklin University of Medicine and ScienceCompletedHIV/AIDS | Substance Use | BisexualityUnited States
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)Completed
-
RANDNational Institute on Drug Abuse (NIDA)CompletedAlcohol Consumption | Drug AbuseUnited States
-
Arizona State UniversityNational Institute on Minority Health and Health Disparities (NIMHD)TerminatedDiet Modification | Parenting | Substance Use Disorders | Cardiovascular Risk Factor | Lifestyle Risk Reduction | Diabetes Mellitus RiskUnited States
-
Moi UniversityIndiana UniversityNot yet recruiting